Summary
Galderma, a Swiss dermatology company, is investing over $650 million in U.S. manufacturing by 2030, with the U.S. accounting for 40% of its sales and being its fastest-growing market. CEO Flemming Ørnskov emphasizes the importance of succeeding in the U.S. market and has strategically located R&D in Boston and headquarters in Miami.